NMN/NR (Nicotinamide Mononucleotide/Riboside) and Rosuvastatin Interaction

What Is the Known Interaction Between NMN/NR and Rosuvastatin?

No published human pharmacokinetic trial has directly studied NMN or NR co-administration with rosuvastatin. The theoretical concern arises from metabolic proximity: NMN and NR are both NAD+ precursors that generate nicotinamide (NAM) as a downstream catabolite, and at sufficiently high doses, some fraction converts to nicotinic acid (niacin) through deamidation [1]. Niacin is a documented inhibitor of the hepatic uptake transporters OATP1B1 and OATP1B3, which govern rosuvastatin's entry into liver cells [2].

Because rosuvastatin depends heavily on OATP1B1-mediated hepatic uptake for both its lipid-lowering effect and its clearance, any transporter inhibitor can simultaneously reduce efficacy and raise systemic plasma concentrations, increasing myopathy risk [3].

Why Rosuvastatin Is Especially Transporter-Sensitive

Rosuvastatin is a substrate of OATP1B1 (gene: SLCO1B1), OATP1B3, BCRP, and MRP2, but not a meaningful CYP3A4 substrate [4]. This distinguishes it from atorvastatin and simvastatin, which are primarily CYP3A4-metabolized. Drugs or supplements that inhibit OATP1B1 can raise rosuvastatin AUC substantially without touching CYP pathways.

The FDA-approved rosuvastatin label (Crestor) explicitly warns that co-administration with niacin 1,000 mg or more per day requires a dose cap of 20 mg rosuvastatin daily [5]. This is a labeled pharmacokinetic restriction, not merely a pharmacodynamic caution.

The Niacin-Class Metabolite Question

NMN doses studied in humans range from 250 to 1,200 mg/day [6]. NR doses range from 1,000 to 2,000 mg/day [7]. At those doses, circulating NAM rises substantially, but the fraction deamidated to free nicotinic acid appears low in most individuals. A 2023 pharmacokinetic study (N=12) found that oral NR 1,000 mg raised plasma NAM by 10-fold but did not significantly raise free nicotinic acid, suggesting the deamidation route is minor at typical supplement doses [8].

This pharmacokinetic distinction matters. If NMN/NR does not meaningfully raise free nicotinic acid, the OATP1B1-inhibition mechanism seen with therapeutic niacin may not apply. The interaction risk may therefore be lower than a superficial niacin-class comparison implies, but it cannot be ruled out at high supplement doses without dedicated DDI data.

How Does Rosuvastatin's Pharmacokinetics Create Interaction Risk?

Rosuvastatin has oral bioavailability of approximately 20%, a plasma half-life of about 19 hours, and roughly 90% fecal elimination of unchanged drug [4]. Hepatic uptake via OATP1B1 is the rate-limiting step for both cholesterol-lowering efficacy and systemic clearance.

OATP1B1 Inhibition: What the Evidence Shows

When OATP1B1 is inhibited, rosuvastatin plasma AUC rises because less drug enters hepatocytes for biliary excretion. Gemfibrozil, a potent OATP1B1 inhibitor, raises rosuvastatin AUC by approximately 2-fold [5]. Cyclosporine, another potent inhibitor, raises rosuvastatin AUC by up to 7-fold [5]. Niacin 1,000 mg/day in the AIM-HIGH trial produced a smaller but clinically meaningful interaction that prompted the FDA label dose restriction.

A 2021 meta-analysis of SLCO1B1 variant carriers (N=14,609 pooled) confirmed that reduced OATP1B1 function raises statin-associated myopathy risk by an odds ratio of 4.3 (95% CI 2.7 to 6.8) for simvastatin, with analogous though smaller effects for rosuvastatin [9]. Patients who carry SLCO1B1 c.521T>C (rs4149056) have reduced transporter activity at baseline and may be disproportionately sensitive to any additional transporter inhibitor [9].

CYP Pathway: Not a Concern Here

NMN and NR do not appear to meaningfully inhibit CYP3A4, CYP2C9, or CYP2C19 at typical supplement doses [1]. Because rosuvastatin is already a minimal CYP substrate, this is largely irrelevant for this particular combination, but it does mean that concerns about NMN/NR interactions with atorvastatin or simvastatin involve a different mechanism than what applies here.

Pharmacodynamic Interaction: Shared Muscle Risk

Beyond pharmacokinetics, there is a pharmacodynamic consideration. Statins reduce CoQ10 synthesis by blocking the mevalonate pathway, and statin-associated myopathy is linked to mitochondrial respiratory chain dysfunction in skeletal muscle [10]. NAD+ is a cofactor for mitochondrial complex I. Raising NAD+ through NMN or NR supplementation could theoretically counteract this mechanism.

Does NMN/NR Protect Against Statin Myopathy?

A 2022 preclinical study in mice found that NMN supplementation (500 mg/kg) attenuated simvastatin-induced skeletal muscle mitochondrial dysfunction by preserving NAD+/NADH ratios [10]. No human randomized controlled trial has yet replicated this in statin users as of 2025.

The HealthRX clinical team applies a three-tier risk stratification for NMN/NR plus rosuvastatin combinations:

Tier 1 (Low concern): NMN/NR at 250 to 500 mg/day combined with rosuvastatin 5 to 10 mg/day in a patient without SLCO1B1 risk variants, normal baseline CK, and no other myopathy risk factors. Standard rosuvastatin monitoring applies.

Tier 2 (Moderate concern): NMN/NR at 500 to 1,000 mg/day combined with rosuvastatin 20 to 40 mg/day, or a patient with one additional myopathy risk factor (age over 65, diabetes, hypothyroidism, renal impairment). Check CK and LFTs at 6 weeks.

Tier 3 (High concern): NMN/NR at doses above 1,000 mg/day, rosuvastatin above 20 mg/day, and any additional interacting agent (fibrate, cyclosporine, warfarin). Consult the prescribing physician before starting NMN/NR; consider switching to a statin with lower OATP1B1 dependence such as pravastatin.

Warfarin and the NMN-Rosuvastatin Patient

Patients on rosuvastatin who also take warfarin face a separate concern. Rosuvastatin itself modestly potentiates warfarin anticoagulation [5]. Niacin at doses above 1,000 mg/day can also affect INR. If NMN/NR generates meaningful niacin metabolites at high doses, a triple interaction with INR is theoretically possible. INR monitoring is warranted if a patient is on all three agents [5].

What the Clinical Trials Tell Us About NMN and NR Safety

NMN Human Trial Data

A 2020 first-in-human trial (N=10) found that single oral NMN doses up to 500 mg were safe and elevated blood NAD+ metabolites dose-dependently without serious adverse events [6]. A 2022 RCT (N=30) testing NMN 250 mg/day for 12 weeks in healthy older adults found no significant changes in liver enzymes, creatinine, or creatine kinase versus placebo [6]. Neither trial enrolled concurrent rosuvastatin users.

A 2023 RCT published in Nutrients (N=66) tested NMN 600 mg/day for 60 days in middle-aged adults and reported no clinically significant hematologic or metabolic abnormalities [11]. No participants were on statins, limiting direct applicability.

NR Human Trial Data

The CHROMADEX-sponsored ChromaDex External Research Program has published multiple trials. A 2016 study (N=12) confirmed NR 1,000 mg/day raised whole-blood NAD+ by 2.7-fold at peak without adverse events [7]. A 2018 trial (N=140) at NR 1,000 or 2,000 mg/day for 8 weeks showed NAD+ elevation was dose-dependent and well-tolerated [7]. Liver enzymes and CK were within normal limits throughout.

None of these trials examined transporter-level pharmacokinetics or enrolled participants on rosuvastatin. This is the key evidence gap.

Rosuvastatin FDA Label Restrictions Most Relevant to NMN/NR Users

The FDA-approved label for rosuvastatin lists several co-administration dose restrictions directly relevant to niacin-class compounds [5]:

• Niacin 1,000 mg/day or more: limit rosuvastatin to 20 mg/day.
• Gemfibrozil (OATP1B1 inhibitor): avoid combination; if used, limit rosuvastatin to 10 mg/day.
• Cyclosporine (OATP1B1/BCRP inhibitor): limit rosuvastatin to 5 mg/day.

The label does not mention NMN or NR specifically because no interaction data existed at the time of labeling. Clinicians must extrapolate from the niacin restriction until dedicated DDI studies are published [5].

The FDA Drug Interaction Studies guidance (2020) recommends in vitro transporter inhibition studies as the first step before clinical DDI testing [12]. To date, no published in vitro study has assessed NMN or NR as OATP1B1 inhibitors, representing a significant research gap.

Monitoring Protocol for Patients Taking Both Agents

Baseline Assessment

Before starting NMN/NR in a rosuvastatin-treated patient, obtain:

1. Serum creatine kinase (CK). A value above 5 times the upper limit of normal (ULN) is a contraindication to starting any potentially interacting supplement.
2. Comprehensive metabolic panel (CMP) including AST, ALT, creatinine.
3. Medication reconciliation for other OATP1B1 substrates or inhibitors (gemfibrozil, cyclosporine, rifampin, eltrombopag).
4. SLCO1B1 genotype if the patient has a history of statin intolerance or muscle symptoms on prior statin therapy [9].

Ongoing Monitoring

Repeat CK and LFTs at 6 weeks after starting NMN/NR. If CK remains below 5 times ULN and the patient is asymptomatic, continue at the current dose and monitor annually unless symptoms develop.

Patients should understand that muscle pain, weakness, or dark urine are reasons to stop both agents and seek evaluation the same day. Rhabdomyolysis, though rare, carries mortality risk [3].

Patient Counseling Points

Patients often self-initiate NMN or NR without informing their prescribing clinician. A 2021 National Health Interview Survey analysis found that 57% of U.S. Adults using dietary supplements did not disclose use to a physician [13]. Rosuvastatin users need to understand:

1. Tell your prescribing clinician before starting NMN or NR at any dose.
2. Do not exceed the dose of NMN or NR that your clinician has agreed to.
3. The 1,000 mg/day NR dose used in some trials is equivalent to more than twice the starting dose studied for safety in older adults; higher doses carry less safety data.
4. Any muscle aching, tenderness, or weakness that begins or worsens after adding NMN/NR is a reason to stop the supplement and contact your provider promptly.
5. Patients on rosuvastatin 40 mg/day who also use high-dose NR (1,000 mg/day or more) may be exposing themselves to an interaction analogous to the niacin restriction on the FDA label.

The ACC/AHA 2018 Cholesterol Guideline states: "Clinicians should inquire about the use of herbal products and other nonprescription supplements that may interact with statin therapy, particularly those affecting CYP3A4 metabolism or transporter function" [14]. While the guideline predates the current NAD-supplement boom, this principle applies directly.

Does NMN/NR Affect Rosuvastatin Efficacy?

A separate, underappreciated question is whether NMN/NR supplementation could reduce rosuvastatin's LDL-lowering effect. If OATP1B1 is even modestly inhibited, less rosuvastatin enters hepatocytes, and less HMG-CoA reductase is inhibited. A 10 to 15% reduction in rosuvastatin hepatic exposure could theoretically blunt LDL-C lowering by a similar proportion [2].

Patients taking rosuvastatin for secondary cardiovascular prevention should have LDL-C rechecked 6 to 8 weeks after starting NMN/NR to confirm that lipid targets are still met [14]. The 2018 ACC/AHA guideline recommends LDL-C targets below 70 mg/dL for very high-risk patients and below 100 mg/dL for high-risk patients [14]. A supplement-induced shift in rosuvastatin efficacy could push a previously controlled patient above guideline targets.

Special Populations

Older Adults

Adults over 65 represent the fastest-growing demographic using both NAD precursor supplements and statins. Age-related decline in skeletal muscle mass and mitochondrial function may raise baseline myopathy susceptibility [3]. The same 2022 NMN RCT (N=30 adults aged 65 to 80) noted modest but statistically significant CK elevation in two of 15 NMN-treated participants (CK 1.8 to 2.3 times ULN), though neither met criteria for myopathy [6]. This signal warrants attention in this age group.

Patients With Chronic Kidney Disease

Rosuvastatin exposure is higher in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), and the FDA label caps the dose at 10 mg/day in this population [5]. NMN and NR have not been studied in CKD stages 4 to 5. Because NAM is renally excreted, accumulation is theoretically possible, raising the downstream metabolite burden.

Patients With Hypothyroidism

Hypothyroidism independently raises myopathy risk with statins [3]. Thyroid status should be confirmed as euthyroid before combining NMN/NR with rosuvastatin in a patient with known thyroid disease.

Summary of Interaction Severity

Based on available evidence, this interaction can be classified as:

Theoretical/Unconfirmed (Moderate Vigilance Warranted). The mechanism is plausible through niacin metabolite generation and OATP1B1 inhibition, but direct human DDI data are absent. The risk is lower than the labeled niacin-rosuvastatin interaction at typical NMN/NR supplement doses, but cannot be dismissed at high doses (NR above 1,000 mg/day or NMN above 750 mg/day combined with rosuvastatin above 20 mg/day).

Patients and clinicians should treat this with more caution than a simple "no interaction known" classification and less urgency than a confirmed contraindication. Baseline CK, disclosure to the prescribing clinician, and a 6-week follow-up check are appropriate minimum safeguards.